This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Eli Lilly's Pipeline Springs a Leak, but Don't Worry

NEW YORK ( TheStreet) -- Never one to shy away from a contrarian position, back in October I rushed to the defense of Eli Lilly (LLY - Get Report) following some harsh words and several downgrades from the Street. Investors had many concerns.

Chief among them were worries about Lilly's pipeline of drugs in development and production. Although I wasn't necessarily Lilly's biggest fan at the time, I didn't agree with the idea the stock, which then traded at around $49 per share, would see the 20% downside suggested by Jefferies analyst Jeffrey Holford, who cut his price target to $40.

Holford cited pipeline fears, which have been a known issue with Lilly for some time. But I believed this was already priced into the stock. Lilly had retraced 15% in the couple of months before Holford's note.

Fast-forward two months later: The Food and Drug Administration (FDA) announced it approved generic versions of Cymbalta, Lilly's blockbuster anti-depressant drug that accounts for more than 25% of Lilly's revenue. Even more interesting: Unlike most generic approvals, FDA announced that it had, in fact, granted not one, but six approvals to, among others, Teva Pharmaceuticals (TEVA).

But here's the thing -- the market didn't flinch. Everyone knew the so-called "patent cliff" was coming. Lilly is still trading at around $49 per share, as of the Monday close -- the same price from back in October when I told you not to worry. It seems that I was right the Street had already priced in the competition from generics.

Having said that, Lilly is still not out of the woods yet. These new generic rivals must still compete on price.  I believe it is safe to say their prices will be much cheaper than Lilly's. Even so, it will take several quarters before Lilly will feel the impact on its consolidated results.

Here's another thing that no one is talking about: the fact that the FDA issued six approvals may actually play into Lilly's favor. Not only must these generics compete with Lilly's branded drug, but they must also compete with each other on price. The production of these new generics will be based on the profits these companies are able to produce.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
LLY $72.16 -1.20%
AAPL $127.18 -1.20%
FB $78.22 -0.75%
GOOG $538.33 -0.45%
TSLA $235.07 2.00%

Markets

DOW 18,062.29 -8.11 -0.04%
S&P 500 2,111.15 -3.34 -0.16%
NASDAQ 5,000.5470 -16.3820 -0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs